CONGRESSES
Highly potent anti-SARS-CoV-2 multi-DARP in therapeutic candidates
Peer Reviewed / PUBMED article Article Open the article here Enquiries Connect with our team of dedicated scientists
Thousands of women donate breast milk for Corona research
Since Tuesday evening, some 5,000 women have responded to Emma Children Hospital’s call to donate breast milk. “Our researchers are very enthusiastic about the overwhelming response,” according to a spokesperson of the Emma Children’s hospital, (A unit of Amsterdam UMC University Hospital).
REPROCELL and VIROCLINICS-DDL Launch New Collaboration in Clinical Research
Rotterdam, The Netherlands, VIROCLINICS-DDL is pleased to announce the signing of a new collaboration agreement with REPROCELL. REPROCELL will provide sample processing services to VIROCLINICS-DDL to support several clinical research projects.
Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership
Caprion-HistoGeneX and Viroclinics-DDL announce a strategic partnership to offer integrated, complementary services to advance infectious disease research and COVID-19 therapeutic development.
Davide Molho, DVM joins Viroclinics Biosciences as Chief Executive Officer
Viroclinics Biosciences B.V. (“Viroclinics”) today announced the appointment of life sciences industry veteran Davide Molho, DVM as the company’s new Chief Executive Officer. Dr. Molho succeeds Bob van Gemen, PhD who has served as the company’s CEO since 2011. This transition is part of a planned succession strategy. Dr. Molho’s appointment will take effect on 1 August 2020.
International partnership progresses UQ COVID-19 vaccine project
9 April 2020 The University of Queensland’s potential COVID-19 vaccine is entering an important new phase of testing with the live coronavirus to determine how effectively it induces protection against coronavirus infection. The UQ team will partner with the Dutch...
Viroclinics-DDL Diagnostic Laboratory Team to Support COVID-19 New Drug Investigations
Preceding weeks have made clear that COVID-19 continues to spread and is paralyzing the world. Times are unprecedented and show us how vulnerable we are and how we depend on each other. As a service organization – highly specialized in virology – we will commit ourselves to realign our resources, equipment and materials to new initiatives to test anti-virals, immune modulators and vaccines in the battle against COVID-19.
Summit Partners Announces Growth Equity Investment in Viroclinics
Global growth equity investor Summit Partners today announced a majority investment in Viroclinics Biosciences B.V., a leading specialized contract research organization (CRO) serving the global biopharmaceutical industry. The funding will be used to fuel continued expansion of Viroclinics’ services, capacity and international presence.
Viroclinics Biosciences and DDL Diagnostic Laboratory Join Forces
Viroclinics Biosciences, a leading virology contract research organization, announced today that it has acquired DDL Diagnostic Laboratory, a leading diagnostic solutions provider. The transaction enhances the combined group’s leading global position in anti-viral and vaccine testing and will serve to accelerate their ambitious growth strategy.
Viroclinics Xplore Joins Trade Mission Life Sciences India
October 13th - October 19th, Delhi & Bangalore Viroclinics Xplore continues its cooperation with The Netherlands Enterprise Agency (RVO). Viroclinics experts will join the upcoming trade mission to India from October 13th to October 19th. The health program of the...
